Literature DB >> 19715116

Induction of neutralization antibodies in mice by Dengue-2 envelope DNA vaccines.

Mariel E Pérez-Vélez1, Teresita García-Nieves, Candimar Colón-Sánchez, Idalí Martínez.   

Abstract

BACKGROUND: Dengue (DEN) viruses have become a public health problem that affects approximately 100 million people worldwide each year. Prevention measures rely on vector control programs, which are inefficient. Therefore, a vaccine is urgently needed.
METHODS: The main goal of our laboratory is to develop an efficient tetravalent DEN DNA vaccine. In this study, we constructed four DEN-2 DNA vaccines expressing prM/env genes, using the homologous leader sequence (VecD2, VRD2E) or the tissue plasminogen activator (tPA) secretory signal (VecD2tpa, VRD2tpa). In vitro expression was tested by transient transfections and Western blot. The immunogenicity and protective efficacy of the vaccine candidates was evaluated in BALB/c mice, using intramuscular (IM) and intradermal (ID) vaccination routes.
RESULTS: Envelope (E) protein expression was detected in transfected COS-7 or 293T cells. We found statistical differences in the antibody responses induced by these vaccine candidates. In addition, the strongest antibody responses and protection were observed when the vaccines were delivered intramuscularly. Moreover, the tPA leader sequence did not significantly improve the vaccine immunogenicity since VecD2 and VecD2tpa induced similar antibody responses.
CONCLUSIONS: We demonstrated that most of our DNA vaccine candidates could induce antibody responses and partial protection against DEN-2 virus in mice. These results provide valuable information for the design and construction of a tetravalent DEN DNA vaccine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19715116      PMCID: PMC2897078     

Source DB:  PubMed          Journal:  P R Health Sci J        ISSN: 0738-0658            Impact factor:   0.705


  41 in total

1.  Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice.

Authors:  Eiji Konishi; Saori Kosugi; Jun-ichi Imoto
Journal:  Vaccine       Date:  2005-11-15       Impact factor: 3.641

Review 2.  Dengue vaccines: problems and prospects.

Authors:  U C Chaturvedi; Richa Shrivastava; Rachna Nagar
Journal:  Indian J Med Res       Date:  2005-05       Impact factor: 2.375

Review 3.  Dengue.

Authors:  Scott B Halstead
Journal:  Lancet       Date:  2007-11-10       Impact factor: 79.321

4.  Evaluation of interferences between dengue vaccine serotypes in a monkey model.

Authors:  Bruno Guy; Veronique Barban; Nathalie Mantel; Marion Aguirre; Sandrine Gulia; Jeremy Pontvianne; Therese-Marie Jourdier; Laurence Ramirez; Veronique Gregoire; Christophe Charnay; Nicolas Burdin; Rafaele Dumas; Jean Lang
Journal:  Am J Trop Med Hyg       Date:  2009-02       Impact factor: 2.345

5.  Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.

Authors:  Wellington Sun; Dennis Cunningham; Steven S Wasserman; Judith Perry; J Robert Putnak; Kenneth H Eckels; David W Vaughn; Stephen J Thomas; Niranjan Kanesa-Thasan; Bruce L Innis; Robert Edelman
Journal:  Hum Vaccin       Date:  2009-01-27

6.  A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge.

Authors:  Sérgio Oliveira De Paula; Danielle Malta Lima; Rafael Freitas de Oliveira França; Alessandra Cristina Gomes-Ruiz; Benedito Antônio Lopes da Fonseca
Journal:  Arch Virol       Date:  2008-11-12       Impact factor: 2.574

7.  Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice.

Authors:  T Kochel; S J Wu; K Raviprakash; P Hobart; S Hoffman; K Porter; C Hayes
Journal:  Vaccine       Date:  1997-04       Impact factor: 3.641

8.  DNA immunisation with Onchocerca volvulus chitinase induces partial protection against challenge infection with L3 larvae in mice.

Authors:  R A Harrison; Y Wu; G Egerton; A E Bianco
Journal:  Vaccine       Date:  1999-11-12       Impact factor: 3.641

9.  An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.

Authors:  J Robert Putnak; Beth-Ann Coller; Gerald Voss; David W Vaughn; David Clements; Iain Peters; Gary Bignami; Hou-Shu Houng; Robert C-M Chen; David A Barvir; Jitvimol Seriwatana; Sylvie Cayphas; Nathalie Garçon; Dirk Gheysen; Niranjan Kanesa-Thasan; Mike McDonell; Tom Humphreys; Kenneth H Eckels; Jean-Paul Prieels; Bruce L Innis
Journal:  Vaccine       Date:  2005-08-15       Impact factor: 3.641

10.  Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity.

Authors:  Julie H McArthur; Anna P Durbin; Jennifer A Marron; Kimberli A Wanionek; Bhavin Thumar; Dennis J Pierro; Alexander C Schmidt; Joseph E Blaney; Brian R Murphy; Stephen S Whitehead
Journal:  Am J Trop Med Hyg       Date:  2008-11       Impact factor: 2.345

View more
  1 in total

1.  Dengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral Serotypes.

Authors:  Monica Poggianella; José L Slon Campos; Kuan Rong Chan; Hwee Cheng Tan; Marco Bestagno; Eng Eong Ooi; Oscar R Burrone
Journal:  PLoS Negl Trop Dis       Date:  2015-07-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.